Your browser doesn't support javascript.
loading
The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description.
McGonigle, John; Murphy, Anna; Paterson, Louise M; Reed, Laurence J; Nestor, Liam; Nash, Jonathan; Elliott, Rebecca; Ersche, Karen D; Flechais, Remy Sa; Newbould, Rexford; Orban, Csaba; Smith, Dana G; Taylor, Eleanor M; Waldman, Adam D; Robbins, Trevor W; Deakin, Jf William; Nutt, David J; Lingford-Hughes, Anne R; Suckling, John.
Afiliación
  • McGonigle J; 1 Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK.
  • Murphy A; 2 Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health, The University of Manchester, Manchester, UK.
  • Paterson LM; 1 Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK.
  • Reed LJ; 1 Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK.
  • Nestor L; 1 Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK.
  • Nash J; 3 Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Elliott R; 1 Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK.
  • Ersche KD; 2 Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health, The University of Manchester, Manchester, UK.
  • Flechais RS; 3 Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Newbould R; 4 Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
  • Orban C; 1 Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK.
  • Smith DG; 5 Imanova Limited, London, UK.
  • Taylor EM; 1 Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, UK.
  • Waldman AD; 4 Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
  • Robbins TW; 2 Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health, The University of Manchester, Manchester, UK.
  • Deakin JW; 6 Centre for Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Imperial College London, London, UK.
  • Nutt DJ; 4 Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
  • Lingford-Hughes AR; 7 Department of Psychology, University of Cambridge, Cambridge, UK.
  • Suckling J; 2 Neuroscience and Psychiatry Unit, Institute of Brain, Behaviour and Mental Health, The University of Manchester, Manchester, UK.
J Psychopharmacol ; 31(1): 3-16, 2017 01.
Article en En | MEDLINE | ID: mdl-27703042
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Conducta Adictiva Tipo de estudio: Clinical_trials / Observational_studies / Systematic_reviews Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Psychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Conducta Adictiva Tipo de estudio: Clinical_trials / Observational_studies / Systematic_reviews Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Psychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido